Get started Log in

HLS — HLS Therapeutics Share News

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Market Cap
CA$133.23m
Enterprise Value
CA$178.10m
Revenue
$55.50m

Brief: HLS Therapeutics Supports Trial To Investigate Effects Of Vascepa Against COVID-19
21/05/2020 21:33
Canada Research Roundup: Cargojet, Kinaxis, Silvercrest Metals
08/05/2020 09:57
Brief: HLS Therapeutics Comments On U.S. District Court Decision On Amarin Patents
31/03/2020 12:40
Canada Research Roundup: Cineplex, Northland Power, Transalta Renewables
20/03/2020 07:32
Brief: Hls Therapeutics Announces Qtrly Loss Per Share $0.40
19/03/2020 10:42
Brief: Hls Therapeutics Provides Investor Update On The Canadian Launch Of Vascepa®
28/01/2020 11:38
Brief: HLS Therapeutics Files New Drug Submission For Perseris In Canada
23/01/2020 11:32
Brief: HLS Therapeutics Announces Health Canada Approval For Vascepa To Reduce Risk Of Cardiovascular Events
31/12/2019 19:22
Canada Research Roundup: Altagas, George Weston, HLS Therapeutics
19/11/2019 13:43
Canada Stocks: TSX futures rise on hopes of U.S.-China trade deal
19/11/2019 12:46
Brief: HLS Therapeutics Qtrly Loss Per Share $0.06
07/11/2019 12:00
Brief: HLS Therapeutics Q2 Loss Per Share $0.06
08/08/2019 11:41
Indivior signs deal to sell schizophrenia drug in Canada
09/05/2019 12:12
Brief: Hls Therapeutics Q1 Loss Per Share $0.14
09/05/2019 11:58
Brief: Indivior Enters Into Exclusive License Agreement With HLS Therapeutics For Perseris
09/05/2019 11:34
Brief: HLS Therapeutics Files New Drug Submission for Vascepa in Canada
29/04/2019 11:05
Brief: HLS Therapeutics Granted Priority Review Status From Health Canada For Vascepa
29/03/2019 19:20
Brief: HLS Therapeutics Q4 2018 Revenue Was $16.7 Mln Compared To $20.4 Mln In Q4 2017
21/03/2019 10:42
Brief: HLS Therapeutics Releases New Data From Vascepa Study
19/03/2019 11:15
Brief: HLS Therapeutics Licenses And Files 'Athelas One' Point-Of-Care Device
14/03/2019 10:42